We are pleased to announce that Dr. Karl Balabanian, Research Director at INSERM and head of the “Chemokines, Lymphoid Niches, and Immunopathology” team at Saint-Louis Hospital and the INSERM U1160 unit associating INSERM and University Paris Cité, will be visiting Armenia this October, where he will meet the teams at the Immune Oncology Research Institute and Yeolyan Hematology and Oncology Center.
Dr. Balabanian is a distinguished immunologist with years of expertise in the genetic, molecular, and functional dynamics of chemokine-receptor interactions. By using bedside-to-bench approaches combining molecular and functional investigations on humans and pre-clinical mouse models, he contributed to seminal breakthroughs including the discovery of ACKR3/CXCR7 and the identification, molecular characterization and modeling of CXCR4 dysfunctions in rare immunodeficiencies, notably the WHIM Syndrome. Dr. Balabanian has co-authored more than 80 peer reviewed articles and has 5 patent applications.
Join us for a talk with Dr. Balabanian on Tuesday October 1, 2024, at 2:00 PM at the Satenik Safaryan Conference Hall, Yeolyan Hematology and Oncology Center, where he will share insights from his recent studies.
About IMMONC
Immune Oncology Research Institute (IMMONC) is dedicated to advancing research aimed at preventing, treating, and ultimately curing cancer while making these innovations accessible to those who need them. If you're interested in joining our team, please feel free to contact us at [email protected] or at +374-41 310-048